New Report: Average Annual Natural Catastrophe Losses for the Insurance Industry Reaches New High of $151 Billion 3-09-2024, 15:00

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

C.K. McWhorter Grants New York City Ballet with McWhorter Family Trust Warrant of Excellence, Recognizing Artistic Innovation and Cultural Leadership 10-04-2024, 13:01